Drug Trial Radar · NCT02091310
Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Feb 2014
Primary completion
Dec 2014
Study completion Feb 2015
Sponsor
- Lead sponsor
- GenfitIndustry
- Sponsor type
- Industry
- Collaborators
- Eurofins Optimed; CardiaBase; PhinC Development
- First posted
- Mar 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In accordance with International Conference on Harmonisation (ICH) E14 guidelines, this Phase I thorough QT (TQT) study will assess the arrhythmogenic potential of GFT505, by evaluating its effect on QT/QTc prolongation in healthy male and female subjects. According to the guidelines, such studies should typically be performed at the expected therapeutic dose and a supra-therapeutic dose that is 3-4-fold higher than the therapeutic dose. GFT505 has previously been tested at 240 mg/d in 14-day multiple administration to healthy overweight subjects (study GFT505-111-7), and both safety and tolerability were very good. However, this dose corresponds to only 2-fold the expected therapeutic dose of 120 mg/d. Therefore, the current TQT study will be preceded by a multiple ascending dose study in which the safety and tolerability of 2 dose levels of GFT505 (300 and 360 mg) corresponding to 2.5 and 3 times the expected therapeutic dose will be evaluated. The highest dose level for which safety and tolerability are considered satisfactory will be the supra-therapeutic dose used in the TQT study.
Conditions
- Healthy Volunteers
Interventions
PlaceboDrug
GFT505Drug
Moxifloxacin 400 mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety parameters such as adverse event monitoring, vital signs, ECG, and clinical laboratory tests (Study Part I)Time frame: 14 days
- Effect on QTcF compared to placebo (Study Part II)Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eurofins Optimed
Gières, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.